ACQUIREDT+30
Cullinan Opprts Fund VCC-Cullinan Opportunities Incorporated VCC Sub Fund 1
Bafna Pharmaceuticals Ltd · NSE
+6,66,000 sh · ₹18.95 Cr
Filed 6 Aug 2026NSE bulk dealview source
FII holding ~flat QoQ
Jun 2026 quarter
Ownership by quarter
Promoter
— 0.0pp
Promoter holding by quarter: Jun 2025 75.0%, Sep 2025 75.0%, Dec 2025 75.0%, Mar 2026 75.0%.
FII
— 0.0pp
FII holding by quarter: Jun 2025 9.3%, Sep 2025 9.3%, Dec 2025 9.3%, Mar 2026 9.3%.
DII
— 0.0pp
Cullinan Opprts Fund VCC-Cullinan Opportunities Incorporated VCC Sub Fund 1
Bafna Pharmaceuticals Ltd · NSE
+6,66,000 sh · ₹18.95 Cr
M7 Global Fund PCC-Aerion
Bafna Pharmaceuticals Ltd · NSE
−6,66,000 sh · ₹18.95 Cr
The announcements library is part of Pro.
Every exchange filing this company makes — results, board meetings, dividends, analyst meets, investor presentations — as filed with NSE / BSE, the day it lands.
16 announcements on record for this company.
DII holding by quarter: Jun 2025 0.0%, Sep 2025 0.0%, Dec 2025 0.0%, Mar 2026 0.0%.
Per-series scale, bounds labeled. Gaps mark quarters without a filing.
Ownership by quarter
Promoter
— 0.0pp
Promoter holding by quarter: Jun 2025 75.0%, Sep 2025 75.0%, Dec 2025 75.0%, Mar 2026 75.0%.
FII
— 0.0pp
FII holding by quarter: Jun 2025 9.3%, Sep 2025 9.3%, Dec 2025 9.3%, Mar 2026 9.3%.
DII
— 0.0pp
DII holding by quarter: Jun 2025 0.0%, Sep 2025 0.0%, Dec 2025 0.0%, Mar 2026 0.0%.
Per-series scale, bounds labeled. Gaps mark quarters without a filing.
The announcements library is part of Pro.
Every exchange filing this company makes — results, board meetings, dividends, analyst meets, investor presentations — as filed with NSE / BSE, the day it lands.
16 announcements on record for this company.